LBA 01 - Late Breaking Abstracts

Presentations

• 02:30pm - 02:40pm PT

  Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial Of Chemoradiation (CRT) +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  Speaker: Benjamin Movsas, MD, FASTRO - Henry Ford Cancer Institute, Detroit
• 02:40pm - 02:50pm PT

  A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: final results from RTOG 3506 (STEEL)

  Speaker: Edwin Posadas, MD - Cedars-Sinai Medical Center, Los Angeles
• 02:50pm - 03:00pm PT

  Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)

  Speaker: Ragu Ratnakumaran, MBBS - Royal Marsden NHS Foundation Trust, Sutton
• 03:00pm - 03:10pm PT

  Addition of Metastasis-Directed Therapy to Standard of Care: Primary Aggregate Analysis and Immunologic Correlatives of the Phase II Randomized EXTEND Trial

  Speaker: Alexander Sherry, MD - Mayo Clinic Rochester, Rochester
• 03:10pm - 03:20pm PT

  Neoadjuvant Chemotherapy with Trastuzumab with or without Concurrent Radiotherapy in HER2-Positive Inoperable Locally Advanced Breast Cancer: A Phase 2 Randomized Trial (NEOTRAC)

  Speaker: Priya Iyer, MD, MBBS - Cancer Institute (WIA), CHENNAI
• 03:20pm - 03:30pm PT

  Baseline and Time-Dependent Predictors of Cognitive Decline for Brain Metastasis Patients Treated with Radiotherapy- A Secondary Analysis of the ATHENA Trial

  Speaker: Haley Perlow, MD - Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland
• 03:30pm - 03:40pm PT

  Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689

  Speaker: Nancy Lee, MD, FASTRO - Memorial Sloan Kettering Cancer Center, New York